GGH
CLSD

GCM Grosvenor Holdings’s Clearside Biomedical CLSD Stock Holding History

GCM Grosvenor Holdings’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,246
Closed -$252K – 20
2024
Q3 		$252K Buy
+13,246
New +$226K 0.04% 23

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GCM Grosvenor Holdings's CLSD Position: Q4 2024 in Review

GCM Grosvenor Holdings sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 13,246 shares — an estimated $252K sold.

GCM Grosvenor Holdings first reported a position in CLSD in Q3 2024 and held it in 1 quarter. The position peaked at $252K in Q3 2024. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • GCM Grosvenor Holdings reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • GCM Grosvenor Holdings sold 13,246 Clearside Biomedical shares in Q4 2024, an estimated $252K.
  • GCM Grosvenor Holdings first reported a position in Clearside Biomedical in Q3 2024 and held it in 1 quarter.
  • GCM Grosvenor Holdings's Clearside Biomedical position peaked at $252K in Q3 2024.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on GCM Grosvenor Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.